These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 7062274)
1. In vivo and in vitro studies on the binding of salicylate to human plasma proteins: evidence for one type of binding site. Cham BE; Bochner F; Imhoff DM; Byrne G; Gunsberg M J Pharmacol Exp Ther; 1982 Mar; 220(3):648-53. PubMed ID: 7062274 [TBL] [Abstract][Full Text] [Related]
2. Protein binding of aspirin and salicylate measured by in vivo ultrafiltration. Ghahramani P; Rowland-Yeo K; Yeo WW; Jackson PR; Ramsay LE Clin Pharmacol Ther; 1998 Mar; 63(3):285-95. PubMed ID: 9542472 [TBL] [Abstract][Full Text] [Related]
3. Salicylate removal during plasma exchange in normal volunteers. White RL; Garnett WR; Poynor WJ; Allen JH; Sharp DE Clin Pharm; 1984; 3(4):396-402. PubMed ID: 6467875 [TBL] [Abstract][Full Text] [Related]
4. Plasma protein binding of salicylic acid, phenytoin, chlorpromazine, propranolol and pethidine using equilibrium dialysis and ultracentrifugation. Verbeeck RK; Cardinal JA Arzneimittelforschung; 1985; 35(6):903-6. PubMed ID: 4026915 [TBL] [Abstract][Full Text] [Related]
5. Protein binding of acetylsalicylic acid and salicylic acid in porcine and human serum. Lee S; Johnson D; Klein J; Eppler J Vet Hum Toxicol; 1995 Jun; 37(3):224-5. PubMed ID: 7571349 [TBL] [Abstract][Full Text] [Related]
6. Salicylate binding by human albumin in the presence of a perfluorochemical emulsion. Parsons DL; Sathe RS Arch Int Pharmacodyn Ther; 1991; 310():5-12. PubMed ID: 1772331 [TBL] [Abstract][Full Text] [Related]
7. A strategy for reaching therapeutic salicylate levels in patients with rheumatoid arthritis using standardized dosing regimens. Furst DE; Blocka K; Cassell S; Dromgoole S; Harris ER; Hirschberg JM; Josephson N; Rupp PA; Paulus HE; Trimble RB J Rheumatol; 1987 Apr; 14(2):342-7. PubMed ID: 3599003 [TBL] [Abstract][Full Text] [Related]
8. Differences in sodium salicylate protein binding in serum and synovial fluid from patients with a knee effusion. Caillier I; Bannwarth B; Monot C; Lapicque F; Netter P; Gaucher A; Royer RJ Int J Clin Pharmacol Ther Toxicol; 1990 Jan; 28(1):7-13. PubMed ID: 2303312 [TBL] [Abstract][Full Text] [Related]
9. Factors affecting the serum protein binding of salicylic acid in newborn infants and their mothers. Hamar C; Levy G Pediatr Pharmacol (New York); 1980; 1(1):31-43. PubMed ID: 7202184 [TBL] [Abstract][Full Text] [Related]
10. Effects of sodium salicylate on elimination kinetics of indomethacin and bile production in dogs. Beck WS; Dietzel K; Geisslinger G; Engler H; Vergin H; Brune K Drug Metab Dispos; 1990; 18(6):962-7. PubMed ID: 1981545 [TBL] [Abstract][Full Text] [Related]
12. The effect of cimetidine on the pharmacokinetics of salicylic acid. Trnavská Z; Trnavský K; Smondrk J Drugs Exp Clin Res; 1985; 11(10):703-7. PubMed ID: 3836857 [TBL] [Abstract][Full Text] [Related]
13. Blood binding of selezen (imidazole salicylate) in man. Zini R; Morin D; Acuto GC; Bianchini C; de Santis F; Tillement JP Int J Clin Pharmacol Ther Toxicol; 1991 Jun; 29(6):242-9. PubMed ID: 1869346 [TBL] [Abstract][Full Text] [Related]
14. Total and free salicylate concentrations in juvenile rheumatoid arthritis. Poe TE; Mutchie KD; Saunders GH; Hanissian AS; Sotello CA J Rheumatol; 1980; 7(5):717-23. PubMed ID: 7441661 [TBL] [Abstract][Full Text] [Related]
15. High-performance liquid chromatography-electrochemical determination of salicylate hydroxylation products as an in vivo marker of oxidative stress. Coudray C; Talla M; Martin S; Fatôme M; Favier A Anal Biochem; 1995 May; 227(1):101-11. PubMed ID: 7668368 [TBL] [Abstract][Full Text] [Related]
16. Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats. Chou RC; Levy G J Pharmacol Exp Ther; 1981 Oct; 219(1):42-8. PubMed ID: 7288614 [TBL] [Abstract][Full Text] [Related]
17. The effect of antacid and aspirin on the bioavailability of isofezolac in man. Rocher I; Henry JF; Flouvat B Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):464-9. PubMed ID: 6500763 [TBL] [Abstract][Full Text] [Related]
18. Plasma and synovial fluid concentrations of salicylic acid and its metabolites in patients with joint effusions. Sitar DS; Chalmers IM; Hunter T J Rheumatol; 1985 Feb; 12(1):134-5. PubMed ID: 3981498 [TBL] [Abstract][Full Text] [Related]
19. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds. Dasgupta A; Jacques M Am J Clin Pathol; 1994 Mar; 101(3):349-53. PubMed ID: 8135194 [TBL] [Abstract][Full Text] [Related]
20. The in vitro and in vivo availability of commercial aspirin in dogs. Owonubi MO; Oehme FW Vet Hum Toxicol; 1981 Apr; 23(2):84-8. PubMed ID: 7292954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]